316 research outputs found
Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report.
Impact of prechamber design and air-fuel ratio on combustion and fuel consumption in a SI engine equipped with a passive TJI
[EN] The increasing concern about Greenhouse Gas (GHG) emissions led the European Union to introduce increasingly stringent limits to the CO2 from road vehicles, with an impact on the sales of passenger cars. Vehicles equipped with Spark-Ignition (SI) engines became more numerous than those equipped with Compression-Ignition (CI) engines, due to the expensive aftertreatment system needed to comply with the restrictive European emission standards. However, SI engines provide lower efficiency than CI engines, due to the low compression ratio and the operation with a stoichiometric air-fuel ratio. Lean combustion can be a solution to increase SI engines' efficiency. Nevertheless, extremely lean mixtures lead to an increase in Cycle-to-Cycle Variability (CCV).The prechamber ignition concept, also known as Turbulent Jet Ignition (TJI), is an attractive solution for lean combustion, without its drawbacks. There are two ways to implement this concept: active TJI and passive TJI. In active TJI, there is an additional fuel supply system inside the prechamber, while passive TJI operates without additional injection. Therefore, passive TJI offers advantages in terms of simplicity, easy packaging, and low cost.In this work, the effects of passive TJI on combustion and performance are investigated by simulation analyses. Particularly, a 1-D engine model was developed to simulate the TJI combustion and validated against the experimental data. Furthermore, model simulations were carried out to assess how the prechamber geometry, in terms of A/V ratio, affects the jet performance, main chamber combustion, and fuel consumption, for different lambda values.The analysis was conducted in a medium-to-high speed and load operating condition, namely 4500 rpm and 13 bar of Indicated Mean Effective Pressure (IMEP), under both stoichiometric and lean mixture. Simulation results demonstrated that the best jet performance and the highest engine efficiency are obtained for medium-tohigh values of prechamber volume and large diameters, both in stoichiometric and lean-burn conditions, defining a common optimum prechamber design regardless of the lambda level.Frasci, E.; Novella Rosa, R.; Pla Moreno, B.; Arsie, I.; Jannelli, E. (2023). Impact of prechamber design and air-fuel ratio on combustion and fuel consumption in a SI engine equipped with a passive TJI. Fuel. 345. https://doi.org/10.1016/j.fuel.2023.12826534
A nudez e sua significação nas elegias latinas
This work aims to provide arguments supporting a metapoetic interpretation of the lexical repertoire of nudity in the elegies of Propertius, Ovid, and Tibullus. The female figures of the elegiac puellae, often described as being naked or wearing transparent clothes, in association with the poet-lover, are confused with poetry itself. This research, therefore, contextualizes the prevailing themes in the erotic-elegiac microcosm of lovers, rivals, and poetic emulators, and specifies terminology related to the setting of nudity in Roman elegy. It also takes into consideration the glossary previously built, and the analysis highlights possible ambiguities that allow for a metapoetic interpretation of the figure of the puella as a metaphor for elegiac poetry.This work aims to provide arguments supporting a metapoetic interpretation of the lexical repertoire of nudity in the elegies of Propertius, Ovid, and Tibullus. The female figures of the elegiac puellae, often described as being naked or wearing transparent clothes, in association with the poet-lover, are confused with poetry itself. This research, therefore, contextualizes the prevailing themes in the erotic-elegiac microcosm of lovers, rivals, and poetic emulators, and specifies terminology related to the setting of nudity in Roman elegy. It also takes into consideration the glossary previously built, and the analysis highlights possible ambiguities that allow for a metapoetic interpretation of the figure of the puella as a metaphor for elegiac poetry.A partir da observação do repertório lexical da nudez nos poetas elegÃacos, Propércio, OvÃdio e Tibulo, o presente trabalho objetiva encontrar elementos que corroborem a sua interpretação metapoética nas elegias latinas. As figuras femininas das puellae elegÃacas, associadas aos poetas amantes, confundem-se com a própria poesia e não raramente são indicadas pela ausência de vestes ou vestes transparentes. A pesquisa contextualiza, portanto, o tema prevalente das elegias romanas, no microcosmo elegÃaco-amoroso, o par amoroso, os rivais amorosos e os êmulos poéticos, além dos termos especÃficos relativos à ambientação da nudez. Em seguida, observa-se o viés de interpretação ambÃgua a respeito da figura da puella e da poesia, pautado no glossário previamente construÃdo
MARTINS, Paulo. A Representação e seus Limites. Pictura Loquens, Poesis Tacens. São Paulo: EDUSP, 2021. 368 pp.
Resenha de MARTINS, Paulo. A Representação e seus Limites. Pictura Loquens, Poesis Tacens. São Paulo: EDUSP, 2021. 368 pp. ISBN: 978-65-5785-007-7
Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
BACKGROUND: Although modest improvements in the survival of patients with non-small cell lung cancer (NSCLC) can be achieved with cisplatin-based chemotherapy (CT), its value is disputed in the geriatric setting. In this study, we evaluate the feasibility of vinorelbine/cisplatin CT for elderly NSCLC patients. METHODS: In this pilot phase I/II trial, all patients received CT with vinorelbine 25 mg/m(2), on day 1 and 8, and cisplatin on day 1, in 28 days-cycles. After stratification for age (up to 75 years), younger patients were sequentially allocated to moderate cisplatin doses (80 mg/m(2 )or 90 mg/m(2)), and older patients were allocated to lower cisplatin doses (60 mg/m(2 )or 70 mg/m(2)). We recruited patients aged over 70 years with newly diagnosed NSCLC, clinical stage III or IV, Karnofsky performance status ≥ 70%, normal serum creatinine, peripheral neuropathy ≤ grade 1, and no prior cancer therapy. RESULTS: Analysis was by intention to treat. Main toxicities (grade 3–4) was as follows: neutropenia, 20%; anemia, 11%; and thrombocytopenia, 2%; alopecia, 55%; fatigue, 11%; and peripheral neurotoxicity, 2%. No grade 3–4 emesis or renal toxicity occurred. Global median time to progression (TTP) and overall survival (OS) were 27.0 (95% CI: 10.1 to 43.7) weeks and 30.1 (95% CI: 24.4 to 35.8) weeks; 1- and 2-year survival rates were 36.3% and 13.2%, respectively. Overall response rate was 50.0% (95% CI: 35.4% to 64.5%), with 1 complete response; no difference on response rate was noticed according to cisplatin dose. Median overall survival was 30.1 weeks, with 1- and 2-year survival rates of 36.3% and 13.2%, respectively. CONCLUSION: Age does not preclude assessment on the role of cisplatin-vinorelbine CT for elderly NSCLC patients with good performance status and adequate bodily functions
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study
The present study aimed at evaluating whether a weekly cisplatin, epirubicin, and paclitaxel (PET) regimen could increase the pathological complete response (pCR) rate in comparison with a tri-weekly epirubicin and paclitaxel administration in locally advanced breast cancer (LABC) patients. Patients with stage IIIB disease were randomised to receive either 12 weekly cycles of cisplatin 30 mg m−2, epirubicin 50 mg m−2, and paclitaxel 120 mg m−2 (PET) plus granulocyte-colony stimulating factor support, or four cycles of epirubicin 90 mg m−2+paclitaxel 175 mg m−2 (ET) every 3 weeks. Overall, 200 patients (PET/ET=100/100) were included in this study. A pCR in both breast and axilla occurred in 16 (16%) PET patients and in six (6%) ET patients (P=0.02). The higher activity of PET was evident only in ER negative (27.5 vs 5.4%; P=0.026), and in HER/neu positive (31 vs 5%; P=0.037) tumours. The two arms yielded similar pCR rate in ER positive (PET/ET=7.5/7.1%) and HER/neu negative (PET/ET=10/6%) patients. At a 39 months median follow-up, 70 patients showed a progression or relapses (PET, 32 vs ET, 38). Anaemia, mucositis, peripheral neuropathy, and gastrointestinal toxicity were substantially more frequent in the PET arm. The PET weekly regimen is superior to ET in terms of pCR rate in LABC patients with ER negative and/or HER2 positive tumours Mature data in terms of disease-free and overall survival are needed to ascertain whether this approach could improve the prognosis of these subsets of LABC patients
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study
The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2weekly, with G-CSF (5 μg/kg days 3–5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% CI = 65–92%] ORR. At a 13-month (range, 4–26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches. © 2001 Cancer Research Campaign http://www.bjcancer.co
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype
Metabolic syndrome (MS) has been shown to increase the risk of breast cancer. Existing data suggest that the strength of metabolic syndrome-breast cancer link varies by intrinsic molecular subtype, but results from worldwide literature are controversial. Primary endpoint of the study was to assess whether MS is a predictor of specific breast cancer (BC) subtype. Secondary endpoint was to determine whether components of MS can individually increase the risk of specific breast cancer subtype
- …